Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Trial Profile

A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Hyaluronidase (Primary) ; Atezolizumab; Cisplatin; Gemcitabine
  • Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 05 Feb 2019 Status changed from recruiting to active, no longer recruiting.
    • 23 Oct 2018 Planned End Date changed from 1 Feb 2020 to 29 Feb 2020.
    • 23 Oct 2018 Planned primary completion date changed from 1 Oct 2019 to 31 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top